A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors

A Phase 1 Study of KSQ-4279 Alone and in Combination in Patients With Advanced Solid Tumors
Condition:   Advanced Solid Tumors
Interventions:   Drug: KSQ-4279;   Drug: KSQ-4279 will be combined in separate cohorts, including combination with an oral PARPi (poly adenosine diphosphate-ribose polymerase inhibitor)
Sponsor:   KSQ Therapeutics, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 16, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments